H
Hbm Holdings Ltd
HKEX:2142
Hbm Holdings Ltd
HKEX:2142
Price:
1.36 HKD
5.43%
Market Closed
Updated:
May 3, 2024
Section:
Relative Value
The Relative Value of one Hbm Holdings Ltd stock under the Base Case scenario is 3.17 HKD. Compared to the current market price of 1.36 HKD, Hbm Holdings Ltd is Undervalued by 57%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Relative Value
Base Case
3.17
HKD
Undervaluation 57%
H
Valuation Multiples
Multiples Across Competitors
Competitors Multiples
Hbm Holdings Ltd Competitors
Hbm Holdings Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| HK |
H
|
Hbm Holdings Ltd
HKEX:2142
|
1B HKD | 1.5 | 5.9 | 0.7 | 0.8 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
287.1B USD | 5.3 | 59.6 | 12.9 | 19.7 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
168.4B USD | 6 | 25.1 | 18 | 27 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
103.5B USD | 7.9 | 26.2 | 17.6 | 19.3 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.3B USD | 10.5 | 28.5 | 22.8 | 23.9 | |
| AU |
|
CSL Ltd
ASX:CSL
|
133.2B AUD | 6.2 | 35.4 | 21.5 | 26.6 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
80.3B USD | 2.9 | 166 | 6.7 | 8.7 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
46.9B USD | 6.9 | -10 | -10.8 | -9.2 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.5B USD | 3.3 | 27 | 13.8 | 17.3 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.2T KRW | 18 | 73.1 | 44.7 | 61.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
